OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) , the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...

today announced that the company will present three posters related to both of its pipeline programs at the American Thoracic Society (ATS) 2025 International Conference (ATS 2025). ATS 2025 is ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific ...

CHICAGO, April 25, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 ...

today announced the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago. The presentation describes the company’s ...

IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible ...

from 12:30 PM to 1:30 PM PDT In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: “Integrating a Different Mechanism of Action, a different Class ...

from 12:30 PM to 1:30 PM PDT In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: "Integrating a Different Mechanism of Action, a different Class of ...

today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 - 10, 2025 in Amsterdam, ...

Presenter: Katharine Price, M.D., Associate Professor of Oncology, Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center, and Principal Investigator of the VERSATILE-003 clinical trial ...